查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1994194

克隆氏症治療市場：全球市場按治療方法、給藥途徑、分銷管道和最終用戶分類的預測——2026-2032年

Crohn's Disease Therapeutics Market by Therapy Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年克隆氏症治療市場價值為 140 億美元，預計到 2026 年將成長至 146.8 億美元，複合年成長率為 5.90%，到 2032 年將達到 209.2 億美元。

主要市場統計數據
基準年 2025 140億美元
預計年份：2026年 146.8億美元
預測年份 2032 209.2億美元
複合年成長率 (%) 5.90%

對克隆氏症治療市場進行全面概述，重點在於臨床因素、未滿足的需求和不斷發展的治療模式。

克隆氏症仍然是一種複雜多樣的發炎性腸道疾病，給臨床醫生、保險公司和生命科學創新者都帶來了挑戰。過去十年，治療方法已從廣泛的免疫抑制療法轉向標靶生物製劑和小分子藥物策略，旨在調節特定的免疫路徑。因此，治療方法決策越來越需要在療效、長期安全性、免疫抗原性以及以患者為中心的因素（例如給藥途徑和治療負擔）之間取得平衡。因此，相關人員必須探討臨床療效、便利性和安全性之間的相互作用如何影響治療方法的採納和持續使用。

變革性的變化正在重塑克隆氏症的治療，包括新的作用機制、成功的臨床試驗、以患者為中心的治療模式以及保險公司的發展趨勢。

克隆氏症的治療格局正在經歷一場變革，這主要得益於生物製藥特異性的提高、口服小分子藥物的出現以及以患者為中心的醫療保健理念的日益普及。包括更具選擇性的白細胞介素和整合素抑制劑在內的新型作用機制，正在改變人們對持續緩解和黏膜癒合的預期，而真實世界數據則進一步明確了它們相對於傳統藥物的地位。同時，製劑和給藥方法的創新正在透過提供更方便的皮下給藥方案和拓展口服製劑的適用範圍，減輕患者的治療負擔。

評估 2025 年美國關稅對治療藥物供應鏈、定價策略、臨床試驗機會和獎勵的累積影響。

美國2025年實施的累積關稅將為藥品供應鏈、商業性定價策略以及更廣泛的藥品取得趨勢創造新的商業環境。關稅導致活性成分、生物製藥成分、管瓶及相關耗材的投入成本增加，可能推高生產和分銷成本。為此，製造商可能會重新評估對海外供應的依賴程度，並加快區域生產投資，並調整籌資策略以降低關稅變化帶來的風險。

對治療藥物的分類、給藥途徑、分銷管道和最終用戶途徑如何影響治療結果和商業策略進行細分分析。

對克隆氏症治療市場的細分分析揭示了治療分類、給藥途徑、分銷管道和最終用戶如何共同影響臨床和商業性結果。根據治療分類，市場可分為生物製劑、免疫抑制劑和小分子藥物。生物製劑可進一步細分，包括整合素抑制劑（如維多珠單抗）、白細胞介素抑制劑（如利沙珠單抗和Ustekinumab單抗）以及TNF抑制劑（如Adalimumab、賽妥珠單抗和Infliximab單抗）。免疫抑制劑包括胺基甲基葉酸和硫嘌呤類藥物，其中Azathioprine和Mercaptopurine是後者的亞類。小分子藥物則以JAK抑制劑為主，託法替尼和Upadacitinib在監管方面和安全性特徵上有差異。

從區域觀點看美洲、歐洲、中東和非洲以及亞太地區的治療方法的引進、法規結構、取得途徑和商業性趨勢。

區域趨勢對於治療創新如何惠及患者以及如何在不同的醫療保健系統中實施商業策略至關重要。在美洲，市場環境的特徵是支付方結構分散、專科藥房網路強大，以及高度成熟的商業性模式，這些都支持差異化的價值提案和基於結果的合約。相較之下，歐洲、中東和非洲（EMEA）地區的監管和報銷環境則較為複雜，集中核准體系與國家層級的准入談判以及不同的衛生技術評估（HTA）實務並存。因此，靈活的打入市場策略和可靠的本地證據至關重要。

該分析檢驗了克隆氏症治療領域中競爭定位、開發平臺、策略聯盟、生產規模和差異化等關鍵公司層面的見解。

克隆氏症治療領域的企業級策略體現了產品組合多元化、定向研發投資和商業性合作的綜合策略。領先的生物製藥公司專注於差異化的作用機制，例如選擇性白細胞介素調節和腸道特異性整合素阻斷，同時也在投資生命週期策略，包括拓展適應症、開發替代製劑和聯合治療。同時，中型和專業生物技術公司則致力於透過生物標記主導的研發和精準醫療方法，在細分市場中佔有一席之地，以滿足尚未被滿足的患者需求。

為指導克隆氏症治療的臨床開發、商業化、患者取得和供應的韌性，提出切實可行的優先建議。

克隆氏症治療領域的領導企業應採取一系列優先行動，以協調臨床開發、商業性化營運和患者可及性的關鍵需求。首先，設計臨床計畫時，應同時關注療效終點和可操作的真實世界指標，以滿足監管機構、付款者和臨床醫生的需求。這種雙重關注強化了其在治療流程中優先地位的合理性。其次，透過地理多元化和合約彈性最佳化供應鏈，降低關稅和地緣政治因素造成的干擾，同時確保接受慢性治療的患者能夠獲得持續的醫療服務。

採用綜合混合方法的研究途徑，結合專家訪談、系統性文獻回顧、供應鏈檢驗和資料三角驗證。

本執行摘要的調查方法融合了多種定性和定量方法，以確保研究結果的可靠性和可重複性。主要研究包括對臨床意見領袖、支付方、專科藥劑師和商業領袖進行結構化訪談，以了解他們對治療結果、推廣障礙和報銷趨勢的實際觀點。除了這些直接意見外，我們還對同行評審的臨床文獻、監管文件和指南更新進行了系統性回顧，以檢驗作用機制和安全性訊號。

整合臨床、商業性和政策影響，以幫助相關人員推進治療方案和以病人為中心的護理路徑。

總之，克隆氏症治療領域的特點是治療方法的快速進步、醫療服務模式的不斷演變以及商業性趨勢的轉變，所有這些因素都要求產業和臨床相關人員具備策略靈活性。雖然生物製藥和口服小分子化合物特異性的提高正在拓展治療選擇，但它們的引入取決於其是否具有可證實的臨床獲益、安全性可控以及是否符合支付方的預期。同時，關稅政策的變化和供應鏈的脆弱性等外部因素進一步增加了營運風險，這些風險必須得到積極應對。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章克隆氏症治療市場（依治療方法分類）

  • 生物製藥
    • 整合素抑制劑
    • 白細胞介素抑制劑
      • 利沙珠單抗
      • Ustekinumab
    • TNF抑制劑
      • Adalimumab
      • 賽妥珠單抗
      • Infliximab
  • 免疫抑制劑
    • 胺基甲基葉酸
    • 硫嘌呤型
      • Azathioprine
      • Mercaptopurine
  • 低分子化合物

第9章克隆氏症治療市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第10章克隆氏症治療市場：依通路分類

  • 醫院藥房
  • 零售藥房
  • 專科診所

第11章克隆氏症治療市場：依最終用戶分類

  • 居家醫療設施
  • 醫院
  • 專科診所

第12章克隆氏症治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章克隆氏症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章克隆氏症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國克隆氏症治療市場

第16章：中國克隆氏症治療藥物市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Arena Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Galapagos NV
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • MorphoSys AG
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Theravance Biopharma, Inc.
  • UCB SA
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-1A1A064C0471

The Crohn's Disease Therapeutics Market was valued at USD 14.00 billion in 2025 and is projected to grow to USD 14.68 billion in 2026, with a CAGR of 5.90%, reaching USD 20.92 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 14.00 billion
Estimated Year [2026] USD 14.68 billion
Forecast Year [2032] USD 20.92 billion
CAGR (%) 5.90%

Comprehensive introduction to Crohn's disease therapeutics landscape emphasizing clinical drivers, unmet needs, and evolving treatment paradigms

Crohn's disease remains a complex, heterogeneous inflammatory bowel condition that challenges clinicians, payers, and life science innovators. Over the past decade therapeutic approaches have shifted from broadly immunosuppressive regimens to targeted biologic and small molecule strategies designed to modulate specific immune pathways. As a result, treatment decision-making increasingly balances efficacy with long-term safety, immunogenicity, and patient-centered considerations such as route of administration and treatment burden. Consequently, stakeholders must navigate a landscape where clinical efficacy, convenience, and safety profiles jointly influence adoption and persistence.

In parallel, healthcare systems are adapting reimbursement models, specialty pharmacy operations, and specialty clinic capabilities to support more personalized treatment algorithms. Real-world evidence initiatives and longitudinal registries are expanding understanding of treatment durability and comparative effectiveness, which in turn shape clinical guidelines and payer coverage. Given these dynamics, strategic planning for product development, market entry, and access requires integrated insights that marry clinical science with commercial realities. This executive summary synthesizes those critical dimensions to help decision-makers identify opportunities and risks within the therapeutic continuum for Crohn's disease.

Transformative shifts reshaping Crohn's disease care including novel mechanisms of action, trial successes, patient-centric delivery models, and payer dynamics

The therapeutic landscape for Crohn's disease is undergoing transformational shifts driven by advances in biological specificity, the emergence of oral small molecules, and a growing emphasis on patient-centric care delivery. Novel mechanisms of action, including more selective interleukin and integrin blockade, are changing expectations for sustained remission and mucosal healing, while real-world evidence continues to refine positioning versus legacy agents. At the same time, innovation in formulation and administration is reducing treatment burden through more convenient subcutaneous dosing and oral options that expand settings of care.

Concurrently, payers and providers are recalibrating access pathways to manage the cost and clinical complexity of newer agents. Value-based contracting, outcomes-based agreements, and specialty pharmacy integration are gaining traction as tools to align cost with observed clinical benefit. Moreover, safety signals and lifecycle management considerations are influencing label expansions and post-marketing requirements, which drive clinicians to adopt risk-management strategies. Taken together, these shifts are producing a more stratified pathway for patients where treatment selection reflects not only disease biology but also delivery preferences, safety tolerance, and system-level incentives.

Assessing the cumulative impact of United States tariffs in 2025 on therapeutics supply chains, pricing strategies, clinical access, and innovation incentives

The introduction of cumulative United States tariffs in 2025 introduces a new operating context for therapeutic supply chains, commercial pricing strategies, and broader access dynamics. Tariff-driven increases in input costs for active pharmaceutical ingredients, biologic components, vials, and ancillary supplies can raise manufacturing and distribution expenditures. In response, manufacturers may reassess offshore supply concentration, accelerate regional manufacturing investments, or revise sourcing strategies to mitigate exposure to tariff volatility.

From a commercial perspective, incremental cost pressures can complicate negotiations with payers and integrated delivery networks, prompting stronger emphasis on total cost of care and outcomes-based arrangements. In the short term, providers and specialty pharmacies may experience inventory and fulfillment stress as suppliers reorganize logistics to accommodate tariff-related constraints. Over the medium term, policy-induced cost differentials can incentivize local production, contractual hedging, and increased vertical integration among suppliers to protect margin and secure supply reliability.

Finally, the tariff environment has implications for innovation incentives. Higher trade barriers can raise the effective cost of bringing complex biologics and high-value small molecules to market in the US, thereby influencing clinical development prioritization and go-to-market sequencing. As a result, strategic planning must account for scenarios that blend procurement complexity with payer sensitivity and evolving manufacturing footprints.

Segmentation insights into how therapy classes, administration routes, distribution channels, and end-user pathways influence outcomes and commercial strategy

A segmentation-aware view of Crohn's therapeutics reveals how therapeutic class, route of administration, distribution channel, and end user jointly shape clinical and commercial outcomes. Based on therapy class, the market divides into Biologics, Immunosuppressants, and Small Molecules, with further granularity within biologics to include Integrin Inhibitors such as vedolizumab, Interleukin Inhibitors including risankizumab and ustekinumab, and TNF Inhibitors such as adalimumab, certolizumab, and infliximab. Immunosuppressants are represented by agents like methotrexate and thiopurines, the latter subgroup including azathioprine and mercaptopurine, while small molecules center on JAK inhibitors with tofacitinib and upadacitinib illustrating divergent regulatory and safety profiles.

In addition, the route of administration-intravenous, oral, and subcutaneous-meaningfully influences clinical adoption, site-of-care economics, and patient preference. Distribution channels from hospital pharmacies to retail pharmacies and specialty clinics create distinct access and dispensing models that affect continuity of care and reimbursement complexity. Finally, end users span home care settings, hospitals, and specialty clinics, each with different capabilities for monitoring, adherence support, and infusion infrastructure. When considered together, these segmentation dimensions indicate that targeted strategies must be tailored to the interplay of mechanism of action, delivery modality, channel logistics, and care setting to optimize uptake and long-term persistence.

Regional perspectives on therapeutic adoption, regulatory frameworks, access pathways, and commercial dynamics across Americas, EMEA, and Asia-Pacific

Regional dynamics are pivotal to how therapeutic innovations reach patients and how commercial strategies are executed across disparate health systems. In the Americas, markets are characterized by fragmented payer landscapes, strong specialty pharmacy networks, and a high degree of commercial sophistication that favors differentiated value propositions and outcomes-based contracting. By contrast, Europe, Middle East & Africa presents a heterogenous regulatory and reimbursement environment in which centralized approvals coexist with country-level access negotiations and diverse health technology assessment practices, requiring adaptive market access strategies and robust local evidence generation.

In the Asia-Pacific region, evolving regulatory harmonization, growing local manufacturing capabilities, and rapid adoption of digital health tools are accelerating access to both biologics and small molecules. Pricing pressures and increasing emphasis on cost-effectiveness are driving tiered launch sequencing and selective commercialization models. Across all regions, stakeholders must align clinical trial design, real-world evidence programs, and supply chain resilience to regional policy nuances and payer expectations. Ultimately, region-specific regulatory frameworks, distribution infrastructures, and patient management norms will determine the pace and shape of adoption for new Crohn's therapeutics.

Key company-level insights examining competitive positioning, R&D pipelines, strategic partnerships, manufacturing scale, and go-to-market differentiation in Crohn's therapeutics

Company-level strategies in Crohn's disease therapeutics reflect a mix of portfolio diversification, targeted R&D investment, and commercial partnerships. Leading biopharmaceutical organizations are concentrating on differentiated mechanisms such as selective interleukin modulation and gut-specific integrin blockade while investing in lifecycle strategies that include label expansions, formulation alternatives, and combination approaches. At the same time, mid-sized firms and specialized biotech companies are pursuing niche positioning through biomarker-driven development and precision medicine approaches to capture segments of the patient population with unmet needs.

Manufacturing scale and supply chain agility are increasingly central to competitive advantage, prompting strategic partnerships, contract manufacturing diversification, and regional footprint expansion. Commercial differentiation hinges on integrated services; companies that complement drug efficacy with patient support programs, hub services for specialty distribution, and digital adherence tools are better positioned to maintain persistence and reduce overall cost of care. In this evolving competitive landscape, partnerships and licensing deals can accelerate market entry and broaden clinical utility, while targeted M&A activity supports vertical integration where it bolsters supply security or accelerates access to proprietary technologies.

Practical and prioritized recommendations guiding clinical development, commercial execution, patient access, and supply resilience for Crohn's therapeutics

Leaders in the Crohn's therapeutics space should adopt a set of prioritized actions that align clinical development with commercial execution and patient access imperatives. First, design clinical programs that generate both robust efficacy endpoints and pragmatic real-world measures to satisfy regulators, payers, and clinicians; this dual focus improves the case for preferred placement in treatment algorithms. Second, optimize supply chains through geographic diversification and contractual resilience to reduce exposure to tariff-driven or geopolitical disruptions and to ensure continuity of care for patients on chronic therapy.

Third, develop comprehensive access strategies that combine value-based contracting with specialty pharmacy integration and digital patient support to maximize adherence and persistence. Fourth, tailor launch sequencing by channel and setting of care-recognizing that intravenous, subcutaneous, and oral modalities demand distinct operational approaches and reimbursement negotiations. Finally, invest selectively in companion diagnostics and biomarker research to support targeted use cases and to clear pathways for premium positioning where clinical differentiation is demonstrable. By prioritizing these actions, organizations can translate clinical promise into sustainable commercial performance while safeguarding patient access.

Comprehensive mixed-method research approach integrating expert interviews, systematic literature review, supply chain validation, and data triangulation

The research methodology underpinning this executive summary integrates multiple qualitative and quantitative approaches to ensure robust, replicable insights. Primary research included structured interviews with clinical thought leaders, payers, specialty pharmacists, and commercial leaders to capture frontline perspectives on therapeutic performance, adoption barriers, and reimbursement dynamics. These firsthand inputs were complemented by systematic review of peer-reviewed clinical literature, regulatory documentation, and guideline updates to validate mechanistic rationale and safety signals.

To strengthen reliability, the analysis incorporated supply chain validation through vendor mapping and distributor interviews, as well as triangulation across data sources to reconcile discrepancies and surface consistent patterns. Scenario analysis was used to stress-test strategic assumptions-particularly around tariff impacts, route-of-care shifts, and payer contracting innovations-so that recommendations reflect plausible operational contingencies. Finally, editorial synthesis prioritized clarity and actionable relevance for decision-makers, with transparent note of limitations where primary evidence is still evolving, thereby enabling informed use of the intelligence in strategic planning.

Conclusion synthesizing clinical, commercial, and policy implications for stakeholders aiming to advance therapeutic options and patient-centric care pathways

In conclusion, the Crohn's disease therapeutics landscape is characterized by rapid therapeutic innovation, evolving care delivery models, and shifting commercial dynamics that together demand strategic agility from industry and clinical stakeholders. Advances in biologic specificity and oral small molecules are expanding treatment options, but adoption will pivot on demonstrable real-world benefits, manageable safety profiles, and alignment with payer expectations. At the same time, external factors such as tariff policy changes and supply chain fragility add layers of operational risk that must be proactively managed.

Therefore, stakeholders should pursue an integrated approach that links clinical differentiation with pragmatic access strategies, resilient manufacturing and distribution, and evidence generation tailored for local health system needs. When executed thoughtfully, such an approach can accelerate appropriate patient access, support sustainable commercial returns, and foster innovation that meaningfully improves long-term patient outcomes. These synthesized implications provide a strategic foundation for teams seeking to navigate near-term disruptions while positioning for enduring success in Crohn's therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Crohn's Disease Therapeutics Market, by Therapy Class

  • 8.1. Biologics
    • 8.1.1. Integrin Inhibitors
    • 8.1.2. Interleukin Inhibitors
      • 8.1.2.1. Risankizumab
      • 8.1.2.2. Ustekinumab
    • 8.1.3. TNF Inhibitors
      • 8.1.3.1. Adalimumab
      • 8.1.3.2. Certolizumab
      • 8.1.3.3. Infliximab
  • 8.2. Immunosuppressants
    • 8.2.1. Methotrexate
    • 8.2.2. Thiopurines
      • 8.2.2.1. Azathioprine
      • 8.2.2.2. Mercaptopurine
  • 8.3. Small Molecules

9. Crohn's Disease Therapeutics Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Crohn's Disease Therapeutics Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Retail Pharmacies
  • 10.3. Specialty Clinics

11. Crohn's Disease Therapeutics Market, by End User

  • 11.1. Home Care Settings
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Crohn's Disease Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Crohn's Disease Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Crohn's Disease Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Crohn's Disease Therapeutics Market

16. China Crohn's Disease Therapeutics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Amgen Inc.
  • 17.7. Arena Pharmaceuticals, Inc.
  • 17.8. AstraZeneca plc
  • 17.9. Bayer AG
  • 17.10. Biogen Inc.
  • 17.11. Boehringer Ingelheim International GmbH
  • 17.12. Bristol Myers Squibb Company
  • 17.13. Celgene Corporation
  • 17.14. Eli Lilly and Company
  • 17.15. Galapagos NV
  • 17.16. Gilead Sciences, Inc.
  • 17.17. GlaxoSmithKline plc
  • 17.18. Janssen Pharmaceuticals, Inc.
  • 17.19. Johnson & Johnson Services, Inc.
  • 17.20. Merck & Co., Inc.
  • 17.21. MorphoSys AG
  • 17.22. Novartis AG
  • 17.23. Pfizer Inc.
  • 17.24. Roche Holding AG
  • 17.25. Sanofi S.A.
  • 17.26. Takeda Pharmaceutical Company Limited
  • 17.27. Theravance Biopharma, Inc.
  • 17.28. UCB S.A.
  • 17.29. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RISANKIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RISANKIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RISANKIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY USTEKINUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY USTEKINUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY USTEKINUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADALIMUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADALIMUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CERTOLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CERTOLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CERTOLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INFLIXIMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INFLIXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MERCAPTOPURINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MERCAPTOPURINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MERCAPTOPURINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 177. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 178. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 179. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 180. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 182. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 208. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 209. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 210. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 212. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 217. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 218. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 219. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 220. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 221. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 222. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)